A Study to Evaluate Skin Angiosarcoma Imaging with Ultrasound

Overview

About this study

The purpose of this study is to to map out the extent of Skin Angiosarcoma disease using ultrasound. This will be compared to the MRI and or PET/CT and with clinical and photographic determination of disease extent confirmed with clinically requested punch biopsies. The patient will be scanned with a commercially avilable GE Logiq 10 machine and then with the 25-30 MHz linear microvessel transducer  for microvessel imaging. These scans will be obtained pretreatment, after 2 cylces of neoadjuvant chemotherapy and after completion of neoadjuvant chemotherapy and radiation therapy prior to surgery. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients over the age of 21.
  • New diagnosis of cutaneous angiosarcoma of the breast or scalp.
  • Provision of signed and dated informed consent form.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Diagnosed with cutaneous angiosarcoma of the breast or scalp and scheduled for trimodality therapy.

Exclusion Criteria:

  • Individual under the age of 21.
  • Unwilling to consent to microvessel ultrasound imaging.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Tiffany Sae-Kho, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20537820

Mayo Clinic Footer